Fc-based half-life extension of human FVIIa - a new player for hemophilia treatment?

被引：0
|
作者：
Margaritis, Paris [1 ]
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
来源：
THROMBOSIS RESEARCH | 2015年 / 135卷 / 05期
关键词：
Hemophilia; Coagulation Factor VIIa; Half-life; Fc fusion; RECOMBINANT FACTOR VIIA; COAGULATION-FACTOR VIIA; ALBUMIN RVIIA-FP; PROPHYLAXIS; INHIBITORS; EFFICACY;
D O I：
10.1016/j.thromres.2015.02.030
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [1] Half-life extended factor VIII for the treatment of hemophilia A
    Tiede, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : S176 - S179
  • [2] New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments
    Wang, Lili
    Ying, Tianlei
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2016, 17 (15) : 1348 - 1352
  • [3] Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life
    Gjolberg, Torleif Tollefsrud
    Frick, Rahel
    Mester, Simone
    Foss, Stian
    Grevys, Algirdas
    Hoydahl, Lene Stokken
    Jorstad, Oystein Kalsnes
    Schlothauer, Tilman
    Sandlie, Inger
    Moe, Morten C.
    Andersen, Jan Terje
    COMMUNICATIONS BIOLOGY, 2022, 5 (01)
  • [4] Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life
    Torleif Tollefsrud Gjølberg
    Rahel Frick
    Simone Mester
    Stian Foss
    Algirdas Grevys
    Lene Støkken Høydahl
    Øystein Kalsnes Jørstad
    Tilman Schlothauer
    Inger Sandlie
    Morten C. Moe
    Jan Terje Andersen
    Communications Biology, 5
  • [5] Hemophilia Extended half-life by PEGylation: ADYNOVI® as a new Treatment Option for Patients with Haemophilia A
    Freyer, Martina
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2018, 45 (03) : 205 - 205
  • [6] Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B
    Ducore, Jonathan M.
    Miguelino, Maricel G.
    Powell, Jerry S.
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (05) : 559 - 571
  • [7] New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins
    Ragni, Margaret V.
    DRUGS, 2015, 75 (14) : 1587 - 1600
  • [8] Adherence to Treatment in Hemophilia: A Comparison of Conventional and Prolonged Half-Life Therapies
    Buckley, B.
    Hagberg, B.
    Zhou, J.
    Eldar-Lisaai, A.
    HAEMOPHILIA, 2016, 22 : 91 - 92
  • [9] New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins
    Margaret V. Ragni
    Drugs, 2015, 75 : 1587 - 1600
  • [10] New Strategy for the Extension of the Serum Half-Life of Antibody Fragments
    Truessel, Sabrina
    Dumelin, Christoph
    Frey, Katharina
    Villa, Alessandra
    Buller, Fabian
    Neri, Dario
    BIOCONJUGATE CHEMISTRY, 2009, 20 (12) : 2286 - 2292
12345